Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

By F. Raal, Narimon Honarpour, D. Blom, G. Hovingh, Feng Xu, R. Scott, S. Wasserman, E. Stein. The Lancet, 2015

661 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/ae71c4c8f903af32e5ddbdf3a9ea64ed53924d1c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Børge G. Nordestgaard

In Surgery

1. Jan Boren
2. A. Tybjærg-Hansen
3. Børge G. Nordestgaard
4. M. Chapman
5. Marja-Riitta Taskinen
6. Alberico L. Catapano
7. S. Gidding
8. I. Graham

Citations in the corpus

• Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015, background): “Of novel therapies in development, monoclonal antibody therapies to PCSK9 (alirocumab, evolocumab and most recently, bococizumab) show the most promise, lowering both LDL-C and Lp(a),(125) although patients homozygous for LDLR-null mutations showed a poor therapeutic response, as expected from the m”